MedTrace Logo

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

NCT02916771 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2025-08-11

Study results available
· View outcomes & findings →

Summary

This research study is evaluating a new drug called "ixazomib" as a possible treatment for Smoldering Multiple Myeloma.

Conditions

  • Smoldering Multiple Myeloma

Interventions

DRUG

Ixazomib

Oral, proteasome inhibitor

DRUG

Lenalidomide

Oral, immunomodulatory agent

DRUG

Dexamethasone

Oral, steroid

Sponsors & Collaborators

Principal Investigators

  • Irene M Ghobrial, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2025-01-08
Completion
2025-01-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02916771 on ClinicalTrials.gov